By ADAM COHEN The debate over the 340B Drug Pricing Program is complicated. However, beyond the arguments over rebates, contract pharmacies, and program intent sits a simpler reality that every stakeholder should plan around. Whatever form 340B takes next, the value an organization captures will depend on its ability to document and justify every discounted transaction with detailed, defensible data. Most organizations are not yet equipped to do that. The stakes are rising, and so is the burden of proof Covered entities purchased roughly $100 billion in outpatient drugs through 3...